Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

An IRF3-POLR2G axis represses liver FGF21 and metabolic transcriptional programs [CUT&Tag Liver IRF3-2D]

ABSTRACT: Inflammatory signaling in the liver reshapes numerous transcriptional programs, but the mechanisms by which innate immune pathways actively repress metabolic gene expression remain poorly understood. Here we show that IRF3, a master regulator of innate immunity that is activated during alcohol-associated liver disease, suppresses the hepatokine FGF21 and broader metabolic gene programs through a non-canonical transcriptional mechanism. IRF3 does not directly occupy metabolic gene loci but instead transcriptionally induces POLR2G, a core RNA polymerase II subunit, through promoter-proximal interferon-stimulated response elements. Elevated POLR2G selectively accumulates at metabolic gene promoters, reduces RNA polymerase II recruitment, and represses transcription of fatty acid oxidation and lipid metabolism genes. This regulatory axis operates in vivo, is conserved from yeast to mammals, and is evident in human alcohol-associated liver disease. These findings identify an IRF3-POLR2G axis that repurposes core transcriptional machinery to coordinate a metabolic-to-inflammatory transcriptional switch in the liver.

ORGANISM(S): Mus musculus

PROVIDER: GSE331024 | GEO | 2026/05/15

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

An IRF3-POLR2G axis represses liver FGF21 and metabolic transcriptional programs [RNA-seq Liver POLR2G]

Project description:Inflammatory signaling in the liver reshapes numerous transcriptional programs, but the mechanisms by which innate immune pathways actively repress metabolic gene expression remain poorly understood. Here we show that IRF3, a master regulator of innate immunity that is activated during alcohol-associated liver disease, suppresses the hepatokine FGF21 and broader metabolic gene programs through a non-canonical transcriptional mechanism. IRF3 does not directly occupy metabolic gene loci but instead transcriptionally induces POLR2G, a core RNA polymerase II subunit, through promoter-proximal interferon-stimulated response elements. Elevated POLR2G selectively accumulates at metabolic gene promoters, reduces RNA polymerase II recruitment, and represses transcription of fatty acid oxidation and lipid metabolism genes. This regulatory axis operates in vivo, is conserved from yeast to mammals, and is evident in human alcohol-associated liver disease. These findings identify an IRF3-POLR2G axis that repurposes core transcriptional machinery to coordinate a metabolic-to-inflammatory transcriptional switch in the liver.

2026-05-15 | GSE331028 | GEO

An IRF3-POLR2G axis represses liver FGF21 and metabolic transcriptional programs [CUT&Tag Liver POLR2G]

2026-05-15 | GSE331025 | GEO

An IRF3-POLR2G axis represses liver FGF21 and metabolic transcriptional programs [RNA-seq Liver IRF3-2D]

2026-05-15 | GSE331029 | GEO

An IRF3-POLR2G axis represses liver FGF21 and metabolic transcriptional programs [CUT&Tag Hepatocytes IRF3-2D]

2026-05-15 | GSE331023 | GEO

An IRF3-POLR2G axis represses liver FGF21 and metabolic transcriptional programs [PRO-seq]

2026-05-15 | GSE331026 | GEO

Fumarate hydratase acetylation by ethanol orchestrates mitochondrial DNA release and cGAS-STING-IRF3 mediated Hepatic stellate cell differentiation

Project description:Alcohol consumption is a major cause of liver fibrosis and further increases liver fibrosis due to other chronic liver diseases. Alcohol induces activation of hepatic stellate cells (HSC), the key fibrogenic cell of the liver, but the metabolic basis for this is not well understood. We identified that acetaldehyde, a metabolite of ethanol, induces lysine acetylation of mitochondrial fumarase (FH1), specifically in lysine residues K80 and K230 leading to reduced FH1 activity and accumulation of the substrate fumarate. The excess mitochondrial fumarate induced mitochondrial DNA (mtDNA) oxidation and release into the cytosol via formation of a mitochondrial permeability pore and voltage-dependent anion channel. The released mtDNA was observed to activate cGAS and subsequently the STING-IRF3 cascade. In a 6-week mouse model of alcohol diet, we observed that FH1 inhibition aggravated, while the STING inhibitor (IFM-004490-7) significantly blocked it. In conclusion, we observed that ethanol derived acetaldehyde mediated FH1 acetylation and subsequent inhibition result in the activation of HSC via the cGAS/STING/IRF3 pathway. This opens the possibility for novel therapeutic approaches to alleviate liver fibrosis by targeting FH1 acetylation and reducing its activity.

2025-09-25 | GSE290734 | GEO

Characterising the transcriptional profile of murine 3T3-L1 adipocytes with altered expression of IRF3.

Project description:The chronic inflammatory state that accompanies obesity is a major contributor to insulin resistance and other metabolic dysfunction features. Despite recent advances in our understanding of the cellular and secreted factors that promote the inflammatory milieu of obesity, we have much less insight into the transcriptional pathways that drive these processes. While most attention has focused on the canonical inflammatory transcription factor NF-KB, other potentially important factors exist, including members of the interferon regultory factor (IRF) family. Here we show that IRF3 expression is upregulated in the adipocytes of obese mice and humans. TLR3/TLR4 activation induces insulin resistance in adipocytes, which can be prevented by IRF3 knockdown. Furthermore, Irf3KO mice display improved insulin sensitivity, associated with reduced intra-adipose and systemic inflammation in the high-fat fed state, enhanced browning of subcutaneous fat, and increased adipose expression of Glut4. Taken together, our data indicates that IRF3 is a major transcriptional regulator of adipose inflammation to maintain systemic glucose and energy homeostasis. Transcriptional profiling of murine 3T3-L1 adipocytes with altered expression of IRF3. Overexpression or knockdown of IRF3 was achieved by lentivirus transduction for 6 days. 3T3-L1 adipocytes with IRF3 knockdown were further treated in the absence or presence of LPS for 6 days. Samples consist of triplicate replica with appropriate control.

2016-05-31 | E-GEOD-81193 | biostudies-arrayexpress

IRF3-mediated pathogenicity in a murine model of human hepatitis A

Project description:Hepatitis A virus (HAV), an hepatotropic picornavirus, is a common cause of acute hepatitis in human populations. Although responsible for considerable morbidity and mortality, the mechanisms underlying HAV-mediated liver injury are poorly understood. Ifnar1-/- mice are susceptible to HAV and when infected recapitulate cardinal features of hepatitis A in humans, including serum ALT elevation, hepatocellular apoptosis, and intrahepatic inflammatory cell infiltrates. In contrast, Mavs-/- mice, while equally permissive for infection, experience no liver injury. Previous studies indicate that HAV pathogenesis in Ifnar1-/- mice is dependent upon MAVS-IRF3 signaling, but leave unresolved the role of IRF3-mediated transcription versus non-transcriptional pro-apoptotic activity of activated IRF3 in HAV-induced liver disease. Here, we compared the intrahepatic transcriptomes of HAV-infected naïve Mavs-/- and Ifnar1-/- mice using high throughput RNA sequencing, and characterized IRF3-mediated transcriptional responses associated with hepatocyte apoptosis and liver inflammation.

2021-08-18 | GSE166353 | GEO

Inflammation causes insulin resistance via IRF3-mediated reduction in FAHFA levels

Project description:Obesity-induced inflammation metabolic dysfunction, but the mechanisms remain elusive. Here we showed that the innate immune factor IRF3 is a direct transcriptional regulator of glucose homeostasis through induction of endogenous FAHFA hydrolase Aig1 in adipocytes. Adipocyte-specific knockout IRF3 protects mice against high-fat diet-induced insulin resistance, whereas overexpression of IRF3 in adipocytes promotes insulin resistance on a high-fat diet. Furthermore, pharmacological inhibition of AIG1 reversed obesity-induced insulin resistance and restored glucose homeostasis in the setting of adipocyte IRF3 overexpression. We therefore, identify the adipocyte IRF3/AIG1 axis as a crucial link between obesity-induced inflammation and insulin resistance and suggest an approach for limiting the metabolic dysfunction accompanying obesity.

2024-02-09 | GSE213048 | GEO

Activation of IRF3 in cardiomyocytes impairs mitochondrial oxidative function through PGC-1α inhibition and drives heart failure

Project description:Heightened sterile inflammation and mitochondrial metabolic dysfunction drives the pathophysiology of heart failure in ischemic cardiomyopathy. Yet, the transcriptional regulators within cardiomyocytes driving crosstalk between inflammation and energy metabolism remain ill-defined. Here we identify elevated Ser396/Ser398 phosphorylation of the type I interferon (IFN) response regulating transcription factor IRF3 in the myocardium of patients and male mice with ischemic cardiomyopathy. Cardiomyocyte-specific IRF3 deficiency attenuates ischemia induced contractile dysfunction. Conversely, IRF3 activation in cardiomyocytes through a phosphomimetic IRF3 mutant represses Ppargc1α expression leading to dysfunctional mitochondrial oxidative phosphorylation, altered metabolic flux in the pentose phosphate pathway/TCA cycle, impaired NAD metabolism and an excessive type I IFN activation, collectively detrimental for cardiac function. Restoring cardiomyocyte-specific Ppargc1α expression in IRF3-overexpressor male mice attenuates contractile dysfunction by augmenting a metabolic shift towards fatty acid oxidation and decreasing inflammatory fibrotic responses. These findings identify IRF3 activation in cardiomyocytes as a transcriptional nexus between cardiac inflammation and metabolic fuel switch contributing to heart failure progression.

2025-12-11 | GSE283352 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data